Sun Pharma

Last updated

Sun Pharmaceutical Industries Limited
Company type Public
ISIN INE044A01036
Industry Pharmaceuticals
Founded1983;41 years ago (1983)
Founder Dilip Shanghvi
Headquarters
Mumbai
,
India
Area served
Worldwide
Key people
Dilip Shanghvi (MD)
Products Pharmaceutical drugs, generic drugs, antiviral drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health
RevenueIncrease2.svg₹44,520 crore (US$5.6 billion) [1]  (2023)
Increase2.svg₹9,408 crore (US$1.2 billion) [1]  (2023)
Increase2.svg₹8,560 crore (US$1.1 billion) [1]  (2023)
Total assets Increase2.svg₹80,743 crore (US$10 billion) [1]  (2023)
Total equity Increase2.svg₹55,995 crore (US$7.0 billion) [1]  (2023)
OwnerDilip Shanghvi (54.48% stake) [1]
Number of employees
41,000+ (2023)
Website sunpharma.com
Footnotes /references
[2] [3]

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering  psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals.  

Contents

History

Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology, ENT, Chest and Consulting Physicians .

The 2015 acquisition of Ranbaxy made Sun Pharma the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally.

Around 70% of Sun Pharma’s revenue is generated from international markets.,. The US and India are the largest markets, accounting for over 60% of the company's turnover;. Manufacturing is across 43 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).

Sun Pharma was listed on the stock exchange in 1994 in an issue that was oversubscribed 55 times. The founding family continues to hold a majority stake in the company.

Acquisitions and joint ventures

Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1995, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and in 1997 acquired MJ Pharma's dosage plant at Halol. In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai. Also in 1997, Sun Pharma initiated their first foray into the international market with the acquisition of Caraco Pharmaceuticals in North America.

In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable acquisitions include Milmet Labs and Cephalexin and 7ADCA actives manufacturing site (1999) Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008).

In 2010, the company acquired a controlling stake in Taro Pharmaceuticals, amongst the largest generic dermatology companies in the US, with operations across Canada and Israel.

In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals, a dermatology device company; and generic pharma company URL Pharma  

In 2014  Sun Pharma entered into a licensing agreement with Merck & Co. Inc. to acquire rights for Tildrakizumab (MK- 3222) for treatment of chronic plaque psoriasis, in order to further strengthen its specialty product pipeline.

To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year.

In 2015, Sun Pharma acquired Ranbaxy in a US$ 4 billion landmark transaction to become the world's 5th largest specialty generic pharmaceutical company.

In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.

The following year Sun Pharma made some significant acquisitions, including 14 prescription brands from Novartis in Japan to enter the Japanese market.

It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.

From 2016 to 2018, Sun Pharma launched some of its new products in the USA. It launched its first branded ophthalmic product, BromSite™ in 2016. In 2017, the company launched its specialty product Odomzo and then in 2018 another specialty product Ilumya™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence. The company entered the Greater China market by partnering with China Medical System Holdings as well as launched a speciality product, CEQUAa, in the United States for the treatment of dry eyes.

In 2023, Sun Pharma acquired Concert Pharmaceuticals, a late-stage biotechnology company in USA, a 60% stake in animal healthcare company - Vivaldis Animal Health and Foods Pvt ltd.  from its existing shareholders for Rs 143.30 crore. 

In January 2024, Sun Pharma entered into a definitive merger with Taro Pharmaceuticals to acquire the remaining stake in Taro Pharma for $347.73 Million. Taro Pharma, the U.S.-based unit of India’s leading drugmaker Sun Pharma Ltd, has unveiled a merger agreement with its parent company. Under this agreement, Sun Pharma, the controlling shareholder of Taro, will acquire all outstanding shares of its subsidiary.

SPARC

In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSE :  SPARC, BSE :  532872). In 2013, SPARC declared revenue of ₹873 million. [4] SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update [5] of its pipeline (NDDS). [6]

Awards

Sun Pharma stood second in the India's Most Reputed Brands (Pharmaceutical) list [7] in a study conducted by BlueBytes, [8] a leading Media Analytics firm in association with TRA Research, [9] a brand insights organization (both a part of the Comniscient Group).

2019

2020

2021

2022

2023

Related Research Articles

<span class="mw-page-title-main">Merck Group</span> German multinational science and technology company

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Mankind Pharma</span> Indian pharmaceutical and healthcare products company

Mankind Pharma is an Indian pharmaceutical and healthcare products company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

<span class="mw-page-title-main">Piramal Group</span> Indian conglomerate

The Piramal Group is an Indian multinational conglomerate that has presence across various sectors such as healthcare, life sciences, drug discovery, financial services, alternative investment and real estate.

<span class="mw-page-title-main">Taro Pharmaceuticals</span> Generic pharmaceutical company

Taro Pharmaceutical Industries is an Israeli research-based pharmaceutical manufacturer publicly listed in the New York Stock Exchange. The company has more than 180 of its own drugs sold all over the world, reaching the markets of over 25 countries. The company's products are mainly sold in the United States, Canada and Israel. Taro Pharmaceutical Industries is reported to be on steady growth since 2008.

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

References

  1. 1 2 3 4 5 6 "Sun Pharma Profit & Loss Statement".
  2. ↑ "Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results" (PDF). mypharmaproducts.store. Sun Pharmaceutical. 4 February 2019. Retrieved 4 February 2019.
  3. ↑ "Annual Report 2020-21" (PDF). Sun Pharmaceutical Industries. Retrieved 12 May 2022.
  4. ↑ "Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts". Moneycontrol.com. Retrieved 2 July 2015.
  5. ↑ "Investor Update on R&D Pipeline" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 12 May 2022.
  6. ↑ "SUN PHARMA ADVANCED RESEARCH COMPANY". Sunpharma.in. Archived from the original on 2 February 2018. Retrieved 2 July 2015.
  7. ↑ "Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list". Archived from the original on 20 August 2016. Retrieved 18 August 2016.
  8. ↑ "Blue Bytes". Bluebytes.info. Retrieved 19 July 2018.
  9. ↑ "TRA". Trustadvisory.info. Retrieved 19 July 2018.
  10. ↑ "Sun Pharma Industries". Forbes. Archived from the original on 23 September 2022. Retrieved 13 November 2022.
  11. ↑ "2019 Recipients". Mahatma Award. Retrieved 6 August 2021.
  12. ↑ "ACEF-Asian Leaders Forum and Awards". www.customerengagement.asia. Retrieved 6 August 2021.
  13. ↑ "The World's Best Employers 2020". Forbes. Retrieved 6 August 2021.
  14. ↑ "Radhika Joshi on LinkedIn: #BASES #innovation #breakthroughinnovations | 28 comments". www.linkedin.com. Retrieved 6 August 2021.
  15. ↑ "Institute of Directors, India on LinkedIn: GPA Results sheet for CSR & HR Excellence - 2020". www.linkedin.com. Retrieved 11 February 2022.
  16. ↑ Award for Sectoral Performance based category-Pharmaceuticals- Sun Pharmaceutical Industries Limited. Dun & Bradstreet India. 19 August 2021. Archived from the original on 9 February 2022. Retrieved 18 February 2022– via YouTube.
  17. ↑ HDA - Healthcare Distribution Alliance [@HDAconnect] (14 June 2021). ".@SunPharma_Live wins the Best New Product Introduction or Promotion DIANA in the "Generic Pharmaceutical Products" category for Epoprostenol. https://t.co/XCYZlqLOCE" (Tweet). Archived from the original on 13 February 2022. Retrieved 18 February 2022– via Twitter.
  18. ↑ Indo-American Chamber of Commerce [@iaccindia] (13 October 2021). "Sun Pharma - The winner of 'Excellence in Innovation' for the year 2021. Mr. C S Muralidharan, Chief Financial Officer of Sun Pharma had collected the award for #SunPharma. #IACCIndia #CorporateAwards #AwardNight #winner #IndoUSrelation #IndoAmericanCorporateExcellenceAwards https://t.co/PxFksVw48c" (Tweet). Archived from the original on 13 February 2022. Retrieved 18 February 2022– via Twitter.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.